Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...

Embark on an intimate journey with heartfelt narratives, poignant reflections, and thoughtful dialogues, hosted by Dr. Lidia Schapira. The award-winning podcast JCO Cancer Stories: The Art of Oncology ...

Clip and Blue—An Easy and Cost-Effective Prechemotherapy Localization Technique in Patients With Breast Cancer Planned for Breast Conservation Uncovering real-world data holds immense potential to ...

Patients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly ...

Pancreatic adenocarcinoma (PDAC) unfortunately remains a highly fatal disease with a 5-year survival rate of only 11%. If surgical resection is not possible, systemic chemotherapy represents the ...

A 64-year-old engineer was diagnosed with a cT2cN0M0, Gleason score 8, adenocarcinoma of the prostate. His prostate-specific antigen level was 15 ng/mL. The case was discussed at the hospital tumor ...

Validation of an Updated Algorithm to Identify Patients With Incident Non–Small Cell Lung Cancer in Administrative Claims Databases Although the potential transformative effect of electronic health ...

Tissue inadequacy and operational challenges may limit lung cancer comprehensive biomarker testing. Here, we describe the initial implementation of a tailored tissue molecular journey at Oncoclínicas ...

Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income Country This study reports on the current status of Radiation ...

Erratum: Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Twenty-four of 58 adults (41 ...

The perspective of all stakeholders involved in clinical trials is critical to addressing disparities in racial/ethnic minority (REM) clinical trial participation. Little is known about clinical trial ...